Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model

Jiang,Zi-Yu; Qin,Shu-Kui; Yin,Xiao-Jin; Chen,Ya-Li; Zhu,Lin

doi:10.3892/etm.2012.583

Synergistic effects of Endostar combined with β-elemene on malignant ascites in a mouse model

Authors:
- Zi-Yu Jiang
- Shu-Kui Qin
- Xiao-Jin Yin
- Ya-Li Chen
- Lin Zhu
View Affiliations

Affiliations: Nanjing University of Chinese Medicine, Nanjing 210046, P.R. China, Department of Medical Oncology, PLA Cancer Center, 81 Hospital of PLA, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210002, P.R. China, Jiangsu Simcere Pharmaceutical Research Institute, Nanjing 210042, P.R. China
Published online on: May 18, 2012 https://doi.org/10.3892/etm.2012.583
Pages: 277-284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To explore an effective combination therapy for malignant ascites, the therapeutic value of the combination of Endostar, a modified recombinant human endostatin, and β-elemene, an active component of a traditional Chinese herb, in an H22 mouse malignant ascites model was investigated. The optimal dose combination of Endostar and β-elemene was determined by evaluating the inhibition of ascites volume and increase in the survival rate of the mice. Other therapeutic effects and the underlying mechanisms were investigated under the optimal dose combination (8 mg/kg Endostar plus 100 mg/kg β-elemene). The mice were randomly divided into four treatment groups and received intraperitoneal injection once a day for eight days: control (0.9% normal saline), Endostar (8 mg/kg), β-elemene (100 mg/kg) or optimal dose combination (8 mg/kg Endostar plus 100 mg/kg β-elemene), respectively. The results of this study revealed that the combination therapy had significant synergistic effects on the inhibition of ascites formation and a deceased number of tumor cells and protein levels in ascites compared with the results of treatment with a single agent. A decreased peritoneal microvascular permeability and reduction in VEGF, MMP-2 and hypoxia inducible factor 1α (HIF1α) was noted in the combination group, when compared with single agent treatment. These studies found that in the ascitic tumor cells, the protein levels of VEGF and MMP-2, as well as levels of VEGF mRNA, were significantly inhibited by the combination therapy. The potentiating effects of the combination of Endostar with β-elemene suggest that this novel therapy may yield an effective therapy for the treatment of malignant ascites.

View Figures

View References

1.	Garrison RN, Kaelin LD, Galloway RH and Heuser LS: Malignant ascites: clinical and experimental observations. Ann Surg. 203:644–651. 1986. View Article : Google Scholar : PubMed/NCBI
2.	Becker G, Galandi D and Blum HE: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 42:589–597. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Tamsma JT, Keizer HJ and Meinders AE: Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol. 12:1353–1357. 2001.PubMed/NCBI
4.	O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997.
5.	Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar
6.	Wang J, Sun Y, Liu Y, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 8:283–290. 2005.(In Chinese).
7.	Li Y, Huang XE, Yan PW, et al: Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev. 11:1119–1123. 2010.PubMed/NCBI
8.	Jiang Z and Qin S: Study progression of recombinant human endostatin (Endostar) for the treatment of malignant serous effusion. Chinese-German J Clin Oncol. 10:435–441. 2011. View Article : Google Scholar
9.	Li QQ, Wang G, Huang F, et al: Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumor cells. J Pharm Pharmacol. 62:1018–1027. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Chen W, Lu Y, Wu J, et al: Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol. 67:799–808. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Zhao J, Li QQ, Zou B, et al: In vitro combination characterization of the new anticancer plant drug β-elemene with taxanes against human lung carcinoma. Int J Oncol. 31:241–252. 2007.
12.	Wang J, Zhang H and Sun Y: Phase III clinical trial of elemenum emulsion in the management of malignant pleural and peritoneal effusions. Zhonghua Zhong Liu Za Zhi. 18:464–467. 1996.(In Chinese).
13.	Kanaoka Y, Maekawa A, Penrose JF, et al: Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem. 276:22608–22613. 2001. View Article : Google Scholar
14.	Cao SS and Zhen YS: Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol. 24:181–186. 1989. View Article : Google Scholar : PubMed/NCBI
15.	Zhang J, Wang X and Lu H: Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase. Cancer Lett. 260:127–136. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar
17.	Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 6:373–378. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Luo JC, Toyoda M and Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 58:2594–2600. 1998.
19.	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Sun XM, Dong WG, Yu BP, et al: Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol. 9:2592–2595. 2003.PubMed/NCBI
21.	Hewitson KS, McNeill LA and Schofield CJ: Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des. 10:821–833. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Fujiwara S, Nakagawa K, Harada H, et al: Silencing hypoxiainducible factor-1α inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol. 30:793–802. 2007.